- Home
- SRZN vs PYXS Comparison
SRZN vs PYXS Comparison
Compare SRZN & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRZN
- PYXS
- Stock Information
- Founded
- SRZN 2015
- PYXS 2018
- Country
- SRZN United States
- PYXS United States
- Employees
- SRZN N/A
- PYXS N/A
- Industry
- SRZN Medicinal Chemicals and Botanical Products
- PYXS Biotechnology: Pharmaceutical Preparations
- Sector
- SRZN Health Care
- PYXS Health Care
- Exchange
- SRZN Nasdaq
- PYXS Nasdaq
- Market Cap
- SRZN 97.3M
- PYXS 79.4M
- IPO Year
- SRZN N/A
- PYXS 2021
- Fundamental
- Price
- SRZN N/A
- PYXS $2.91
- Analyst Decision
- SRZN Strong Buy
- PYXS Strong Buy
- Analyst Count
- SRZN 2
- PYXS 5
- Target Price
- SRZN $38.50
- PYXS $7.75
- AVG Volume (30 Days)
- SRZN 29.4K
- PYXS 691.6K
- Earning Date
- SRZN 11-05-2025
- PYXS 11-11-2025
- Dividend Yield
- SRZN N/A
- PYXS N/A
- EPS Growth
- SRZN N/A
- PYXS N/A
- EPS
- SRZN N/A
- PYXS N/A
- Revenue
- SRZN $12,621,000.00
- PYXS $2,820,000.00
- Revenue This Year
- SRZN N/A
- PYXS N/A
- Revenue Next Year
- SRZN N/A
- PYXS N/A
- P/E Ratio
- SRZN N/A
- PYXS N/A
- Revenue Growth
- SRZN N/A
- PYXS N/A
- 52 Week Low
- SRZN $5.90
- PYXS $0.83
- 52 Week High
- SRZN $18.17
- PYXS $5.39
- Technical
- Relative Strength Index (RSI)
- SRZN 71.33
- PYXS 73.77
- Support Level
- SRZN $13.28
- PYXS $2.10
- Resistance Level
- SRZN $15.06
- PYXS $2.78
- Average True Range (ATR)
- SRZN 0.73
- PYXS 0.18
- MACD
- SRZN 0.15
- PYXS 0.02
- Stochastic Oscillator
- SRZN 67.62
- PYXS 77.16
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.